A new trading day began on Monday, with Compass Therapeutics Inc (NASDAQ: CMPX) stock price down -4.35% from the previous day of trading, before settling in for the closing price of $3.22. CMPX’s price has ranged from $0.76 to $3.63 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -6.06%. With a float of $83.22 million, this company’s outstanding shares have now reached $137.59 million.
In an organization with 32 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.8%, operating margin of -1501.0%, and the pretax margin is -1292.88%.
Compass Therapeutics Inc (CMPX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Compass Therapeutics Inc is 39.51%, while institutional ownership is 43.50%.
Compass Therapeutics Inc (CMPX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.60% during the next five years compared to 12.88% growth over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Here are Compass Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 31.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 498.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.8 million. That was inferior than the volume of 2.73 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 55.28%. Additionally, its Average True Range was 0.31.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 76.69%, which indicates a significant increase from 68.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 145.52% in the past 14 days, which was higher than the 102.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.89, while its 200-day Moving Average is $1.54. However, in the short run, Compass Therapeutics Inc’s stock first resistance to watch stands at $3.17. Second resistance stands at $3.25. The third major resistance level sits at $3.34. If the price goes on to break the first support level at $3.00, it is likely to go to the next support level at $2.91. The third support level lies at $2.83 if the price breaches the second support level.
Compass Therapeutics Inc (NASDAQ: CMPX) Key Stats
With a market capitalization of 423.78 million, the company has a total of 137,589K Shares Outstanding. Currently, annual sales are 0 K while annual income is -42,490 K. The company’s previous quarter sales were 850 K while its latest quarter income was -13,080 K.
